BRENTUXIMAB VEDOTIN
brentuximab vedotin 50 mg injection, 1 vial
BRENTUXIMAB VEDOTIN (12646N)
12646N
Manner of administration:Injection
Restriction
Indication: CD30 positive peripheral T-cell lymphoma, non-cutaneous type
Treatment phase: Initial treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 200 mg | # of repeats: 5 | DPMA: $17,780.23 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Adcetris
(brentuximab vedotin 50 mg injection, 1 vial)
|
||||